Guangzhou Baiyunshan Pharmaceutical Holdings (00874) published its annual performance with a net profit attributable to shareholders of 2.983 billion yuan, an increase of 5.21% year-on-year.

Guangzhou Baiyunshan Pharmaceutical Holdings (00874) announced its annual results for the year ending on December 31, 2025. The group achieved operating revenue of 77.656 billion yuan, an increase of 3.55% year-on-year; net profit attributable to the company's shareholders was 2.983 billion yuan, an increase of 5.21% year-on-year; basic earnings per share were 1.835 yuan, and a cash dividend of 0.45 yuan per share is proposed. In 2025, the group will focus on the strategic positioning of biopharmaceutical health, relying on industrial advantages, fully tapping into its own resources and assets, comprehensively promoting production and operational work, and driving continuous stable growth in business. Further promote the standardized and standardized construction of Chinese medicinal material planting bases, continuously enhance control over the production and supply of key Chinese medicinal materials; consolidate the development advantages of characteristic raw materials, continuously enrich the product line of characteristic raw materials, and at the same time, increase the expansion layout of new raw material drugs, steadily expand the domestic and international markets. Continuously strengthen deep cooperation with leading chain stores and e-commerce, further strengthen advantageous varieties, tap into dormant varieties, cultivate blockbuster new products, grasp quality and safety, continuously improve product quality, enhance market core competitiveness, and promote the stable development of the pharmaceutical business. During this reporting period, the sales revenue of products such as Xiaokewa, Baoji series, Amoxicillin series, Angong Niuhuang pills, Shujin Jianwa pills, anti-inflammatory and pain relief cream, Methyl orange peel glycyrrhiza, and Candarosartan were achieved with fast year-on-year growth.